Publications:
Our Research

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines

Safety, efficacy, and immunogenicity of the NVXCoV2373 vaccine

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates

The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century

Safety, immunogenicity, and efficacy of the NVX-CoV2373 Covid-19 vaccine in adolescents a randomized clinical trial

Immunogenicity and safety of NVX-CoV2373 as a Homologous or Heterologous booster: A phase 3 randomized clinical trial in adults

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial